Advertising to healthcare professionals
Compliance and awareness in the field service
After updating its product advertising for doctors, a marketing authorization holder requested a legal review of the brochures and documents. We ensured that the advertising content complied with the pharmaceutical advertising regulations and was in line with the information for healthcare professionals.
Compliance and awareness in the field service
A marketing authorisation holder requested a legal review of brochures and documents following an update of its product advertising aimed at physicians. We ensured that the advertising content complies with the medicinal product advertising regulations and is consistent with the summary of product characteristics.
Drawing on many years of experience in advising on medicinal product advertising, both for professionals and for the general public, we support marketing departments and the sales force in expanding advertising compliance through pragmatic solutions.
From A to B via CH
International distribution of medicinal products
An internationally active pharmaceutical company based in Switzerland handles the Europe-wide distribution of its medicinal products from Switzerland. The task was to clarify the conditions under which direct deliveries between EU countries with administrative processing via Switzerland are possible and...
International distribution of medicinal products
An internationally active pharmaceutical company based in Switzerland manages the Europe‑wide distribution of its medicinal products from Switzerland. The key questions were under which conditions direct deliveries between EU countries with administrative processing via Switzerland are possible and which authorisations are required for this purpose.
All players in the pharmaceutical supply chain must comply with the principles of good manufacturing practice (GMP) and good distribution practice (GDP) in order to protect patients from falsified medicinal products entering the legal supply chain. Drawing on our experience in Swiss and European pharmaceutical law as well as in matters relating to the bilateral agreements (Mutual Recognition Agreement, MRA), we were able to contribute to the design of the distribution structure.